Lilly seals cardiovascular R&D deal with Zydus

By Nick Taylor

- Last updated on GMT

Related tags Clinical trial Eli lilly

Eli Lilly’s pursuit of outsourcing deals continues unabated with the pharma major entering into a cardiovascular R&D collaboration with Zydus Cadila that has been described as a “new paradigm for global alliances”.

The deal is the latest in a string of outsourcing deals inked by Lilly, which got underway in August when it signed a 10 year preclinical toxicology agreement with Covance and sold its laboratory to the contract research organisation (CRO).

Lilly has also entered into deals with Icon, Quintiles, i3 and a R&D joint venture with India’s Jubilant Organosys in recent months. The pharma major has now increased the level of its R&D outsourcing through the deal with Zydus, which will see the Indian company taking responsibility for a chunk of Lilly’s cardiovascular research in an agreement that could span six years.

Pankaj Patel, chairman and managing director of Zydus, said: “We have built strong discovery and development capabilities in the cardiometabolic disease area and this is a wonderful opportunity to unite efforts, share expertise, complement strengths and develop new potential cardiovascular therapies. We are delighted to embark on this programme with Lilly and create a new benchmark in collaborative research programmes​.”

Cardiovascular disease in JV’s sights

The collaboration has been established to discover and develop potential drug candidates against a novel target, with the research primarily focused on cardiovascular diseases.

Zydus’ role within this covers drug discovery, lead identification and optimisation and conducting preclinical studies and clinical trials up to Phase II human proof-of-concept.

In return Lilly will provide expertise and feedback regarding toxicology, ADME (adsorption, distribution, metabolism and excretion), chemistry, biology, clinical and regulatory aspects when deemed necessary to increase the probability of success. Lilly will also supply the chemical starting points.

The deal includes the option for Lilly to license any of the resulting molecules at different stages of development, with Zydus receiving up to $300m (€226m) in milestone payments. Zydus would also receive royalties from any product that reaches commercialisation.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers